Participant‐reported pain relief of 50% or greater · adults with fibromyalgia
Mirtazapine showed no clear difference in participant‐reported pain relief of 50% or greater (substantial… compared with placebo (low certainty).
1 finding from 1 review
Safety Any serious adverse event · adults with fibromyalgia
It is very uncertain whether mirtazapine changes safety: serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
Mirtazapine showed no clear difference in tolerability: withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with fibromyalgia
Mirtazapine may leads to higher participant‐reported pain relief of 30% or greater (moderate… compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · adults with fibromyalgia
Mirtazapine showed no clear difference in participant‐reported sleep problems (scale: 0 to 28; higher scores… compared with placebo (low certainty).
1 finding from 1 review
Somnolence · adults with fibromyalgia
Mirtazapine may leads to higher somnolence compared with placebo (low certainty).
1 finding from 1 review
Weight gain · adults with fibromyalgia
Mirtazapine may leads to higher weight gain compared with placebo (low certainty).
1 finding from 1 review
Efficacy as a continuous outcome · adults with cancer and depression
1 finding from 1 review
Efficacy as a dichotomous outcome · adults with cancer and depression
It is very uncertain whether mirtazapine changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCA) (very low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · adults with cancer and depression
It is very uncertain whether mirtazapine changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCA) (very low certainty).
1 finding from 1 review
Mental state: 2a. Negative symptoms ‐ No clinical important improvement ‐ negative symptoms (SANS) · schizophrenia
It is very uncertain whether mirtazapine adjunct changes mental state: specific negative symptoms ‐ clinically important… compared with placebo adjunct (very low certainty).
1 finding from 1 review
Mental state: clinically important change in mental state · schizophrenia
It is very uncertain whether mirtazapine adjunct changes mental state: overall mental state ‐ clinically important change* compared with placebo adjunct (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia
Mirtazapine adjunct showed no clear difference in leaving the study early for any reason compared with placebo adjunct (moderate certainty).
1 finding from 1 review
Clinical response: mean score/change in global state: mean CGI‐S score (high = poor) Medium term (12 weeks) · schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service utilisation outcomes: hospital admission or days in hospital · schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effect/event: clinically important extrapyramidal adverse events ‐ akathisia (medium term) · schizophrenia
Mirtazapine adjunct may leads to lower adverse effects: extrapyramidal ‐ clinically important change… compared with placebo adjunct (low certainty).
1 finding from 1 review
Intervention not reported
Mirtazapine RCTs: 1 Participants: 406 · people with chronic pain Interventions: duloxetine (all doses combined), milnacipran (all doses combined), mirtazapine (all doses…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
Mirtazapine standard dose RCTs: 2 Participants: 457 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
2 participants
Very low
Intervention not reported
Mirtazapine standard dose RCTs: 1 Participants: 422 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Low